Cetuximab (Erbitux)

-----Original Message-----
From: U.S. Food & Drug Administration (FDA)
Sent: 11/8/2011 12:55:06 PM
To: guyperea@live.com
Subject: Cetuximab (Erbitux)

FDA approved cetuximab (Erbitux, ImClone LLC, a wholly-owned subsidiary of Eli-Lilly and Company) in combination with platinum-based therapy plus 5-florouracil (5-FU) for the first-line treatment of patients with recurrent locoregional disease and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).  (November 7, 2011) More Information: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm278957.htm

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to guyperea@live.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420